Prof. Nir Peled, MD, PhD
Lung cancer is the leading cause of cancer-related death worldwide, with more than 1.7 million deaths per year. Prof. Peled focuses on the wide translational and clinical perspectives of lung cancer, including personalized targeted therapy in lung cancer, biomarker development, immuno-oncology, and early detection of this disease.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used to treat a variety of cancers including non-small cell lung cancer. Response to tyrosine kinase inhibitors in lung cancer can be subdivided into two groups. The first group, in which treatment can be very successful, includes patients carrying sensitizing EGFR mutations in their tumors. The second group of patients presents primary mutations in EGFR that do not respond to treatment with TKIs; most of these patients have primary in frame insertion resistance mutations to TKIs in exon 20 of EGFR; this accounts for approximately 10% of all cases of EGFR mutations (around 30,000 cases per year). Currently, there is no approved treatment for this group of patients, and this represents a very strong unmet medical need in the area of lung cancer treatment.